Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $2,027,600.00 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CAO Edward Carr sold 20,000 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the transaction, the chief accounting officer directly owned 20,000 shares in the company, valued at $2,027,600. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Dianthus Therapeutics Stock Down 4.3%

Shares of NASDAQ:DNTH traded down $4.31 on Friday, reaching $96.81. The company had a trading volume of 2,829,340 shares, compared to its average volume of 933,748. Dianthus Therapeutics, Inc. has a twelve month low of $32.22 and a twelve month high of $117.88. The stock has a 50-day moving average price of $107.04 and a 200 day moving average price of $92.81. The stock has a market capitalization of $5.29 billion, a P/E ratio of -23.33 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -3.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush upped their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. JPMorgan Chase & Co. began coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They issued an “overweight” rating and a $135.00 price objective on the stock. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $129.83.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at about $401,990,000. Wellington Management Group LLP grew its position in Dianthus Therapeutics by 24.4% during the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after buying an additional 634,099 shares in the last quarter. ABS Investment Management LLC acquired a new stake in Dianthus Therapeutics during the second quarter worth about $194,960,000. Polar Capital Holdings Plc increased its stake in Dianthus Therapeutics by 34.3% during the fourth quarter. Polar Capital Holdings Plc now owns 1,004,728 shares of the company’s stock valued at $41,405,000 after acquiring an additional 256,725 shares during the period. Finally, Jennison Associates LLC bought a new position in Dianthus Therapeutics during the first quarter valued at about $40,713,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.